These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 23966249)

  • 1. Using AD biomarker research results for clinical care: a survey of ADNI investigators.
    Shulman MB; Harkins K; Green RC; Karlawish J
    Neurology; 2013 Sep; 81(13):1114-21. PubMed ID: 23966249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception.
    Weiner MW; Veitch DP; Aisen PS; Beckett LA; Cairns NJ; Green RC; Harvey D; Jack CR; Jagust W; Liu E; Morris JC; Petersen RC; Saykin AJ; Schmidt ME; Shaw L; Shen L; Siuciak JA; Soares H; Toga AW; Trojanowski JQ;
    Alzheimers Dement; 2013 Sep; 9(5):e111-94. PubMed ID: 23932184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Measurement of longitudinal β-amyloid change with 18F-florbetapir PET and standardized uptake value ratios.
    Landau SM; Fero A; Baker SL; Koeppe R; Mintun M; Chen K; Reiman EM; Jagust WJ
    J Nucl Med; 2015 Apr; 56(4):567-74. PubMed ID: 25745095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship of Hippocampal Volume to Amyloid Burden across Diagnostic Stages of Alzheimer's Disease.
    Trzepacz PT; Hochstetler H; Yu P; Castelluccio P; Witte MM; Dell'Agnello G; Degenhardt EK;
    Dement Geriatr Cogn Disord; 2016; 41(1-2):68-79. PubMed ID: 26625159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception.
    Weiner MW; Veitch DP; Aisen PS; Beckett LA; Cairns NJ; Green RC; Harvey D; Jack CR; Jagust W; Liu E; Morris JC; Petersen RC; Saykin AJ; Schmidt ME; Shaw L; Siuciak JA; Soares H; Toga AW; Trojanowski JQ;
    Alzheimers Dement; 2012 Feb; 8(1 Suppl):S1-68. PubMed ID: 22047634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cognitive reserve and clinical progression in Alzheimer disease: A paradoxical relationship.
    van Loenhoud AC; van der Flier WM; Wink AM; Dicks E; Groot C; Twisk J; Barkhof F; Scheltens P; Ossenkoppele R;
    Neurology; 2019 Jul; 93(4):e334-e346. PubMed ID: 31266904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Education on Alzheimer's Disease-Related Neuroimaging Biomarkers in Healthy Controls, and Participants with Mild Cognitive Impairment and Alzheimer's Disease: A Cross-Sectional Study.
    Wada M; Noda Y; Shinagawa S; Chung JK; Sawada K; Ogyu K; Tarumi R; Tsugawa S; Miyazaki T; Yamagata B; Graff-Guerrero A; Mimura M; Nakajima S;
    J Alzheimers Dis; 2018; 63(2):861-869. PubMed ID: 29689728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuronal injury biomarkers and prognosis in ADNI subjects with normal cognition.
    Toledo JB; Weiner MW; Wolk DA; Da X; Chen K; Arnold SE; Jagust W; Jack C; Reiman EM; Davatzikos C; Shaw LM; Trojanowski JQ;
    Acta Neuropathol Commun; 2014 Mar; 2():26. PubMed ID: 24602322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Joint Assessment of Quantitative 18F-Florbetapir and 18F-FDG Regional Uptake Using Baseline Data from the ADNI.
    Ben Bouallègue F; Mariano-Goulart D; Payoux P;
    J Alzheimers Dis; 2018; 62(1):399-408. PubMed ID: 29439345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Japanese and North American Alzheimer's Disease Neuroimaging Initiative studies: Harmonization for international trials.
    Iwatsubo T; Iwata A; Suzuki K; Ihara R; Arai H; Ishii K; Senda M; Ito K; Ikeuchi T; Kuwano R; Matsuda H; ; Sun CK; Beckett LA; Petersen RC; Weiner MW; Aisen PS; Donohue MC;
    Alzheimers Dement; 2018 Aug; 14(8):1077-1087. PubMed ID: 29753531
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mapping the effects of ApoE4, age and cognitive status on 18F-florbetapir PET measured regional cortical patterns of beta-amyloid density and growth.
    Murphy KR; Landau SM; Choudhury KR; Hostage CA; Shpanskaya KS; Sair HI; Petrella JR; Wong TZ; Doraiswamy PM;
    Neuroimage; 2013 Sep; 78():474-80. PubMed ID: 23624169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patterns of Cortical and Subcortical Amyloid Burden across Stages of Preclinical Alzheimer's Disease.
    Edmonds EC; Bangen KJ; Delano-Wood L; Nation DA; Furst AJ; Salmon DP; Bondi MW;
    J Int Neuropsychol Soc; 2016 Nov; 22(10):978-990. PubMed ID: 27903335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Pragmatic, Investigator-Driven Process for Disclosure of Amyloid PET Scan Results to ADNI-4 Research Participants.
    Erickson CM; Karlawish J; Grill JD; Harkins K; Landau SM; Rivera-Mindt MG; Okonkwo O; Petersen RC; Aisen PS; Weiner MW; Largent EA
    J Prev Alzheimers Dis; 2024; 11(2):294-302. PubMed ID: 38374735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of Progressive Mild Cognitive Impairment by Multi-Modal Neuroimaging Biomarkers.
    Xu L; Wu X; Li R; Chen K; Long Z; Zhang J; Guo X; Yao L;
    J Alzheimers Dis; 2016; 51(4):1045-56. PubMed ID: 26923024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brain amyloid imaging--FDA approval of florbetapir F18 injection.
    Yang L; Rieves D; Ganley C
    N Engl J Med; 2012 Sep; 367(10):885-7. PubMed ID: 22931256
    [No Abstract]   [Full Text] [Related]  

  • 16. 18F PET with florbetapir for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).
    Martínez G; Vernooij RW; Fuentes Padilla P; Zamora J; Bonfill Cosp X; Flicker L
    Cochrane Database Syst Rev; 2017 Nov; 11(11):CD012216. PubMed ID: 29164603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cognition and amyloid load in Alzheimer disease imaged with florbetapir F 18(AV-45) positron emission tomography.
    Rosenberg PB; Wong DF; Edell SL; Ross JS; Joshi AD; Brašić JR; Zhou Y; Raymont V; Kumar A; Ravert HT; Dannals RF; Pontecorvo MJ; Skovronsky DM; Lyketsos CG
    Am J Geriatr Psychiatry; 2013 Mar; 21(3):272-8. PubMed ID: 23395194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 18F-FDG Is a Superior Indicator of Cognitive Performance Compared to 18F-Florbetapir in Alzheimer's Disease and Mild Cognitive Impairment Evaluation: A Global Quantitative Analysis.
    Khosravi M; Peter J; Wintering NA; Serruya M; Shamchi SP; Werner TJ; Alavi A; Newberg AB
    J Alzheimers Dis; 2019; 70(4):1197-1207. PubMed ID: 31322568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of the Incremental Diagnostic Value of Florbetapir F 18 Imaging in Patients With Cognitive Impairment: The Incremental Diagnostic Value of Amyloid PET With [18F]-Florbetapir (INDIA-FBP) Study.
    Boccardi M; Altomare D; Ferrari C; Festari C; Guerra UP; Paghera B; Pizzocaro C; Lussignoli G; Geroldi C; Zanetti O; Cotelli MS; Turla M; Borroni B; Rozzini L; Mirabile D; Defanti C; Gennuso M; Prelle A; Gentile S; Morandi A; Vollaro S; Volta GD; Bianchetti A; Conti MZ; Cappuccio M; Carbone P; Bellandi D; Abruzzi L; Bettoni L; Villani D; Raimondi MC; Lanari A; Ciccone A; Facchi E; Di Fazio I; Rozzini R; Boffelli S; Manzoni L; Salvi GP; Cavaliere S; Belotti G; Avanzi S; Pasqualetti P; Muscio C; Padovani A; Frisoni GB;
    JAMA Neurol; 2016 Dec; 73(12):1417-1424. PubMed ID: 27802513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects.
    Trojanowski JQ; Vandeerstichele H; Korecka M; Clark CM; Aisen PS; Petersen RC; Blennow K; Soares H; Simon A; Lewczuk P; Dean R; Siemers E; Potter WZ; Weiner MW; Jack CR; Jagust W; Toga AW; Lee VM; Shaw LM;
    Alzheimers Dement; 2010 May; 6(3):230-8. PubMed ID: 20451871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.